<DOC>
	<DOCNO>NCT02736448</DOCNO>
	<brief_summary>This randomized phase II , parallel group study . Patients gastro-entero-pancreatic neuroendocrine tumor ( GEP-NET ) well differentiate G1 - G2 ( ki67≤ 20 % ) G3 ( ki67≤ 50 % ) , somatostatin receptor ( SSR ) positive 18-FDG positive enrol study randomly assign 2 different arm : - Arm Lu-PRRT-Cap : oral low dose capecitabine association Lu-PRRT ( 3.7 Gbq per cycle x 7 cycle ) follow long acting octreotide lanreotide ( SS-LAR ) ; OR - Arm Lu-PRRT : Lu-PRRT ( 3.7 gigabecquerel ( Gbq ) per cycle x 7 cycle ) follow SS-LAR .</brief_summary>
	<brief_title>177Lutethium - Peptide Receptor Radionuclide Therapy ( Lu-PRRT ) Plus Capecitabine Versus Lu-PRRT FDG Positive , Gastro-entero-pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>This randomized phase II , parallel group study . Patients gastro-entero-pancreatic neuroendocrine tumor ( GEP-NET ) well differentiate G1 - G2 ( ki67≤ 20 % ) G3 ( ki67≤ 50 % ) , SSR positive 18-fluorodeoxyglucose ( FDG ) positive enrol study randomly assign 2 different arm : - Arm Lu-PRRT-Cap : oral low dose capecitabine association Lu-PRRT ( 3.7 Gbq per cycle x 7 cycle ) follow long acting octreotide lanreotide ( SS-LAR ) ; OR - Arm Lu-PRRT : Lu-PRRT ( 3.7Gbq per cycle x 7 cycle ) follow SS-LAR . The primary objective evaluate progression free survival ( PFS ) two arm . The secondary objective : ) efficacy ( disease control rate , DCR ) , ii ) acute late toxicity , iii ) overall survival ( OS ) . The investigator plan enroll 176 patient period 36 month period 36 month follow</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Histopathologic diagnosis gastroenteropancreatic neuroendocrine tumor , well differentiate G1 G2 ( ki67≤20 % ) G3 ( ki67≤50 % ) 2 . Male Female , age &gt; 18 year 3 . Measurable disease accord RECIST 1.1 criterion 4 . Patients documented disease admit therapeutic phase diagnostic receptor imaging , OctreoScan , significant uptake tumor ( grade 2 3 , accord Rotterdam scale ) and/or PET/CT 68Gallium ( 68Ga ) peptide image tumor uptake least equal liver background 5 . Patients documented disease admit therapeutic phase 18FDG PET/CT positive standardize uptake value ( SUV ) &gt; 2.5 least one documented lesion . 6 . Non operable advance disease 7 . Documented progression standard therapy long act octreotide lanreotide ( SSLAR ) , Everolimus PNETs platinum base therapy G3 patient . 8 . Patients finish prior standard chemotherapy therapeutical radiotherapy ( le 25 % body surface ) least 6 week 9 . Life expectancy great 6 month . 10 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 11 . Adequate haematological , liver renal function : haemoglobin ≥ 9 g/dL , absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , total bilirubin ≤ 2.5 X upper normal limit ( UNL ) , Alanine transaminase ( ALT ) &lt; 2.5 X UNL ( &lt; 5 X UNL presence liver metastasis ) , creatinine &lt; 2 mg/dL . 12 . Concomitant SSsubcutaneous assumption allow case carcinoid syndrome 13 . If female childbearing potential highly effective birth control method , accord guideline `` Recommendation related contraception pregnancy test clinical trial '' , ( 2014_09_15 section 4.1 ) ( See Appendix H ) mandatory . Highly effective birth control method require begin screen visit continue 6 month follow last treatment study drug . Negative serum pregnancy test female childbearing potential within 14 day start treatment . Male patient female partner childbearing potential must use 2 acceptable method birth control ( 1 must include condom barrier method contraception ) start screen continue throughout study period 6 month final study drug administration . Two acceptable method birth control thus include Condom ( barrier method contraception ) one follow require ( establish use oral , injected implant hormonal method contraception female partner ; placement intrauterine device ( IUD ) intrauterine system ( IUS ) female partner ; additional barrier method like occlusive cap spermicidal foam/gel/film/cream/suppository female partner ; tubal ligation female partner ; vasectomy procedure result infertility ( eg , bilateral orchiectomy ) , 6 month . 14 . Participant willing able give inform consent participation study . 15 . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . 1 . Ki 67 index &gt; 50 % 2 . FDG PET negative 3 . Patients treat chemotherapy therapeutic radiotherapy within 6 week 4 . More 25 % body surface radiotherapy 5 . Patients treat previous radiometabolic therapy adsorb dose kidney 23 Gy 1,2 Gy bone marrow surrogate dosimetry , Total Cumulative Activity ( TCA ) &gt; 250 millicurie ( mCi ) 90Y dotatoc &gt; 800 ( mCi ) 177Lutethium ( 177Lu ) dotatate 6 . All acute toxic effect prior therapy ( include surgery radiation therapy , chemotherapy ) must resolve grade ≤ 1 accord National Cancer Institute Common Terminology Criteria Adverse Events Version 4.0 ( CTCAE ) 7 . Life expectancy minor 6 month . 8 . ECOG performance status &gt; 2 9 . Participation another clinical trial investigational agent within 30 day prior study screen . 10 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 11 . History allergic reaction attribute compound similar chemical biologic composition 12 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . 13 . Known hypersensitivity Octreotide and/or Lanreotide , and/or somatostatin correlate peptide 14 . Known hypersensitivity capecitabine component 15 . Known hypersensitivity 5 fluorouracil . 16 . Other know malignant neoplastic disease patient 's medical history diseasefree interval le 5 year ( except previously treat basal cell carcinoma situ carcinoma uterine cervix ) ;</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GEP-NET tumor</keyword>
	<keyword>Lu-PRRT</keyword>
	<keyword>177Lutethium - Peptide Receptor Radionuclide Therapy</keyword>
	<keyword>gastro-entero-pancreatic neuroendocrine tumor</keyword>
	<keyword>18-FDG Positron Emission Tomography ( PET ) positive</keyword>
	<keyword>low dose capecitabine</keyword>
</DOC>